Amycretin Tracker App
Track Every Dose. See Every Trend.
Shotlee is the free way to track your Amycretin protocol from day one. Amycretin is a GLP-1 + Amylin dual agonist by Novo Nordisk. Log every injection, monitor your weight trajectory, record side effects, and build a clean data history that you can review with your healthcare provider at any time.
Key Tracking Features
Precise dose logging with timestamps and injection site rotation
Visual weight and body composition trend charts over time
Side effect correlation to help optimize your protocol with your doctor
Clinical Snapshot
SC 20mg (36 wks)
-22.0%
Subcutaneous highest dose showed 22% mean weight loss over 36 weeks with no plateau observed.
Oral (12 wks)
-13%
Oral formulation achieved 13% weight loss in only 12 weeks in Phase 1 — an unusually rapid result.
T2D SC (36 wks)
-14.5%
In Phase 2 for Type 2 diabetes, subcutaneous amycretin showed 14.5% weight loss at 36 weeks.
What This Means for Your Tracking Right Now
Whether you are already on Amycretin or considering it as a future option, building clean tracking data now gives you a major advantage. Having historical weight, symptom, and dose records makes it far easier to evaluate how well any protocol is working for your body.
Use Shotlee to log your body weight trend, dose consistency, appetite changes, GI symptoms, blood pressure, and any lab markers your doctor recommends. If you ever switch medications, that historical data lets you compare outcomes with precision instead of guesswork.
Shotlee supports all major metabolic protocols today, so you can stay systematic regardless of which specific medication you are on.
Tracking Priorities in Shotlee
Weekly dose logs, side effect timing, body weight, waist measurements, and key lab snapshots are the highest-value signals to capture now in the Shotlee app.
Vital Protocol FAQs
Is Amycretin a GLP-1 or amylin drug?
It is both. Amycretin is a dual GLP-1 and amylin receptor agonist, meaning it activates two different hormone pathways simultaneously. This makes it mechanistically distinct from pure GLP-1 drugs like Semaglutide. Track your protocol in the Shotlee app.
Can I get Amycretin now?
No, Amycretin is still investigational. Phase 3 trials are expected to begin in Q1 2026. Use Shotlee to track your current protocol and build baseline data.
Will there be an oral version?
Yes, Novo Nordisk is developing both subcutaneous and oral formulations. The oral version showed 13% weight loss in just 12 weeks in Phase 1. Track your progress in Shotlee regardless of formulation.
Start Tracking Your Protocol Today
Track your Amycretin protocol with Shotlee and make every decision from clean, visible data instead of guesswork.
🚀 Use Shotlee for Free